Post by
cool888 on Apr 22, 2022 6:54pm
$RVV - Good post on Yahoo by Crusader - thx.
#Bucillamine
Note to new Investors and why I consider Revive Therapeutics is such a great opportunity at this moment.
Revive has 2 separate statistical endpoints giving the drug Bucillamine the opportunity to receive EUA (Emergency Use Authorization) to immediately bring to market Bucillamine for #1 study for patients based on Covid 'Symptoms' and #2 study of Covid patients based on 'Hospitalization'.
These Studies are independent of each other so DOUBLE chances for EUA success. If the 'Symptoms' study were to not be approved, we still have our main study for 'Hospitalizations' ongoing.
Also Bucillamine received Orphan Drug Status for a completely different trial based on Lung IPF (Idiopathic pulmonary fibrosis) plus Revive has several other psilocybin (mushroom) Verticals and IP's (Intellectual Properties) making it worth way more than these few pennies of our current share price.
In my opinion we are virtually de-risked. GLTA